How much does Invokana cost?
The list price for Invokana, a medication used to treat type 2 diabetes, is approximately $300 for a 30-day supply. However, actual out-of-pocket costs for patients can vary significantly depending on insurance coverage, pharmacy, and any available patient assistance programs.
What factors influence the price of Invokana?
Several elements contribute to the final cost of Invokana for consumers. These include the specific dosage prescribed, whether the medication is available as a generic, and the formulary tier assigned by an individual's health insurance plan [1]. Pharmacy benefit managers and insurance companies negotiate pricing with pharmaceutical manufacturers, which can lead to different costs at various pharmacies [1].
Can I get financial assistance for Invokana?
Patients may be eligible for financial assistance programs that can reduce their out-of-pocket expenses. The manufacturer of Invokana offers a savings card that can lower the cost for eligible commercially insured patients. Details about these programs can typically be found on the drug's official website or by consulting with a healthcare provider or pharmacist [1].
When does Invokana's patent expire?
Understanding patent expiration is crucial for predicting future pricing trends and the potential introduction of lower-cost generic alternatives. Information regarding the patent status of Invokana and its potential generic entry dates can be found through specialized resources like DrugPatentWatch.com [2].
How does Invokana's price compare to similar diabetes medications?
Invokana belongs to a class of drugs known as SGLT2 inhibitors. Its price is generally in line with other medications in this class, such as Jardiance and Farxiga. However, comparisons should consider the specific indication, dosage, and patient outcomes, as well as the negotiated prices available through insurance plans [1].
What is the active ingredient in Invokana?
Invokana's active ingredient is canagliflozin [3]. Canagliflozin works by blocking a protein in the kidneys called sodium-glucose cotransporter 2 (SGLT2). This blockage prevents the kidneys from reabsorbing sugar back into the blood, leading to more sugar being removed from the body through urine [3].
Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com
3. Invokana Prescribing Information